EVH

Evolent Health, Inc.

7 filings tracked

healthcarehealthcare technologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Evolent Health is navigating a strategic inflection point, transitioning toward a scalable, high-margin model centered on its Performance Suite.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the growth narrative, Evolent's operational engine shows signs of strain. Revenue growth of 2.6% was vastly outpaced by an 8.2% surge in the cost of revenue, pushing the cost-of-revenue ratio to a concerning 83.1% of sales.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every EVH filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing reveals a company in a high-stakes transition. Evolent is betting its future on the maturation of new, high-acuity value-based care contracts that offer higher pricing but carry significant initial risk. The tension lies between the improving unit economics and the deteriorating aggregate margins, as the 'go-live' phase of new contracts temporarily inflates the Medical Expense Ratio and drains operating cash flow. Investors are left to weigh the promise of operating leverage against the reality of a debt-laden balance sheet and extreme customer concentration. While the narrowing net loss and SG&A cuts are positive signals, the surge in claim reserves and the shift to negative operating cash flow suggest that the path to profitability is fraught with execution risk. The overall impact of the filing is a mixed signal: the platform is growing and pricing power is present, but the financial safety margin is thin.

Selected Quarter

Core Takeaway

Evolent is transitioning to a higher-priced value-based care model, but initial implementation costs are compressing margins and draining cash.

Investor Lens

The trade-off is between the long-term scalability of the Performance Suite and the immediate risk of a liquidity crunch due to debt and claim reserves.

Watch Next

The normalization of the Medical Expense Ratio (MER) in upcoming quarters and the impact of SOFR rate changes on interest expense.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

bearishMay 7

Cost of revenue grew 8.2% while revenue only grew 2.6%, leading to a spike in MER to 93.3%.

margin compression

80%

bullishMay 7

Net loss narrowed significantly from $72.3M to $26.6M year-over-year.

earnings beat

40%

neutralMay 7

Exchange of Series A Preferred Stock for Second Lien Loan Facility completed.

debt restructure

50%

Filing History

10-QMay 7, 2026

Expand Sequence

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.